We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+0.13%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$86.7M
AUM Growth
+$23.2M
Cap. Flow
+$43.8M
Cap. Flow %
50.53%
Top 10 Hldgs %
100%
Holding
8
New
2
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
GLUE icon
Monte Rosa Therapeutics
GLUE
+$42.4M
2
TPST icon
Tempest Therapeutics
TPST
+$3.48M

Top Sells

Rank Stock Value
1
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLUE icon
1
Monte Rosa Therapeutics
GLUE
$1.86B
$39.2M 45.22%
+5,652,922
New +$42.4M
CRSP icon
2
CRISPR Therapeutics
CRSP
$4.68B
$19.6M 22.62%
498,558
– –
CTNM
3
Contineum Therapeutics
CTNM
$529M
$13.5M 15.51%
918,163
– –
SKYE icon
4
Skye Bioscience
SKYE
$21.6M
$5.68M 6.55%
2,007,704
– –
RPTX
5
DELISTED
Repare Therapeutics
RPTX
$3.47M 4%
2,646,657
– –
TPST icon
6
Tempest Therapeutics
TPST
$13.9M
$2.93M 3.37%
+269,773
New +$3.48M
ADVM
7
DELISTED
Adverum Biotechnologies
ADVM
$2.37M 2.73%
506,821
– –
GRTS
8
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-3,561,150
Closed -$2.07M

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q4 2024 Portfolio in Review

As of Q4 2024, Versant Venture Management held 8 positions worth $86.7M, up 36% from $63.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management deployed $43.8M of net new capital in Q4 2024, opening 2 new positions. Its largest new stake was Monte Rosa Therapeutics: 5,652,922 shares worth $39.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Gritstone bio, Inc. Common Stock, an estimated $2.07M sold.

  • Versant Venture Management's largest Q4 2024 buy was Monte Rosa Therapeutics: 5,652,922 shares worth $39.2M.
  • Versant Venture Management fully exited Gritstone bio, Inc. Common Stock in Q4 2024, selling an estimated $2.07M.
  • Versant Venture Management's ten largest holdings make up 100% of its $86.7M portfolio in Q4 2024.
  • Versant Venture Management opened 2 new positions and closed 1 in Q4 2024.
  • Versant Venture Management's portfolio value rose 36% quarter-over-quarter to $86.7M.

Based on Versant Venture Management's 13F filing for Q4 2024, filed 12 Feb 2025.